Zymeworks to Participate in Upcoming Investor Conferences.

Zymeworks, a clinical-stage biotechnology company, announced that management will participate in the following investor conferences: Citi's Biopharma Back to School Conference, Wells Fargo Healthcare Conference, Cantor Global Healthcare Conference, and Morgan Stanley Annual Global Healthcare Conference. Management will participate in one-on-one meetings and fireside chats at each conference.

VANCOUVER, British Columbia, Aug. 19, 2025 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company focused on developing novel, multifunctional biotherapeutics, has announced its participation in several upcoming investor conferences. The company will engage with investors at the Citi’s Biopharma Back to School Conference, Wells Fargo Healthcare Conference, Cantor Global Healthcare Conference, and Morgan Stanley Annual Global Healthcare Conference.

Management of Zymeworks will participate in one-on-one meetings and fireside chats at each conference. These events provide an opportunity for investors to gain insights into the company’s pipeline, strategic partnerships, and future prospects.

Citi’s Biopharma Back to School Conference
- Date: September 3, 2025
- Location: Boston, MA
- Event: One-on-one meetings

Wells Fargo Healthcare Conference
- Date: September 4, 2025
- Time: 4:30 pm ET
- Location: Boston, MA
- Event: One-on-one meetings and fireside chat

Cantor Global Healthcare Conference
- Date: September 5, 2025
- Time: 8:35 am ET
- Location: New York, NY
- Event: One-on-one meetings and fireside chat

Morgan Stanley Annual Global Healthcare Conference
- Date: September 8, 2025
- Time: 3:20 pm ET
- Location: New York, NY
- Event: One-on-one meetings and fireside chat

Zymeworks is committed to improving the standard of care for difficult-to-treat diseases such as cancer, inflammation, and autoimmune diseases. The company has engineered and developed zanidatamab, a HER2-targeted bispecific antibody, which has received regulatory approvals in the U.S., Europe, and China. Zanidatamab is currently being evaluated in multiple global clinical trials for its potential as a best-in-class treatment for multiple HER2-expressing cancers.

Zymeworks’ robust pipeline includes wholly-owned product candidates such as ZW171, ZW191, and ZW251, which are actively recruiting for phase 1 studies and expected to enter clinical trials in 2025. The company’s strategic partnerships with global biopharmaceutical companies further enhance its capabilities in developing innovative therapeutic solutions.

For more information about Zymeworks, visit [www.zymeworks.com](http://www.zymeworks.com) and follow @ZymeworksInc on X.

References:
[1] https://www.marketscreener.com/news/zymeworks-announces-participation-in-upcoming-investor-conferences-ce7c51ddd98afe24
[2] https://finance.yahoo.com/news/zymeworks-announces-participation-upcoming-investor-100000081.html
[3] https://www.barchart.com/story/news/34239935/zymeworks-announces-participation-in-upcoming-investor-conferences